Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

ROTTERDAM, The Netherlands, September 7, 2011 /PRNewswire/ --

SIMPLE Antibody™ platform continues to demonstrate clear advantages in therapeutic antibody discovery


arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, will provide an update on this year's significant corporate progress  during a presentation by its CEO Tim Van Hauwermeiren at the BioPharm America conference in Boston, MA, USA (http://www.ebdgroup.com/bpa/).

In his presentation on Friday, September 9, Mr. Van Hauwermeiren will showcase the speed with which arGEN-X has developed its pipeline of novel therapeutic antibody candidates in cancer and inflammatory disease. In less than two years of operations, the Company has identified three completely novel lead antibodies of unprecedented specificity and potency and progressed them into preclinical studies. arGEN-X is also combining the power of its SIMPLE Antibody™ platform with POTELLIGENT® Technology licensed from BioWa, Inc., to increase the cytotoxic potency of its therapeutic leads even further.

The arGEN-X presentation will also announce the successful fulfilment of all milestones in its first biopharma collaboration, only five months from its initiation in January 2011. Upon completion of this program, arGEN-X delivered a panel of unique, diverse antibodies against a technically complex target provided by the partner. This success demonstrated how the SIMPLE Antibody™ platform could generate antibodies with outstanding qualities, even against targets beyond the reach of other antibody platforms.

Speaking further about the exciting developments at arGEN-X, Mr. Van Hauwermeiren said:

"The signficant progress we have made in 2011 is proof that our unique SIMPLE Antibody™ Platform is tra
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...  DURECT Corporation (Nasdaq: DRRX ) ... successful completion of a Phase 1 clinical trial ... is an endogenous, small-molecule, new chemical entity (NCE), ... such as nonalcoholic fatty liver disease (NAFLD) and ... such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... March 2, 2015 BD (Becton, Dickinson and ... medical technology company, today announced the acquisition of CRISI ... medical technology company dedicated to improving the safety and ... position in helping address preventable medication errors and improve ... into an exclusive partnership in June 2013 to jointly ...
(Date:3/2/2015)...  Akron Children,s Hospital has been designated a Diagnostic ... of Radiology (ACR), making it the first hospital in ... hospital in the United States ... from the ACR as a DICOE provides validation that ... with national benchmarks," says Dr. Michael Rubin , ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5BD Acquires CRISI Medical Systems 2BD Acquires CRISI Medical Systems 3Akron Children's designated ACR Diagnostic Imaging Center of Excellence 2
...  Mission Pharmacal Company announces the recent formation ... unit, a wholly owned subsidiary of Mission, ... and human resources (HR) support.  Alamo will ... Northeastern United States presence, which also includes ...
... (NYSE: WPI ) today announced that ... a settlement with Mallinckrodt Inc. on outstanding patent ... Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets.  Mallinckrodt filed ... United States District Court for the District of ...
Cached Medicine Technology:Mission Pharmacal Launches Alamo Pharma Services 2Mission Pharmacal Launches Alamo Pharma Services 3Watson Reaches Settlement with Mallinckrodt Over Exalgo(R) 2
(Date:3/2/2015)... March 02, 2015 Doctors in Novara, ... a better predictor of outcomes for people with mesothelioma ... details of the new study on the Surviving ... the University of Eastern Piedmont followed the cases of ... treatment for excess lung fluid. , “Persistent lung ...
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... Over the last five years the ultrasound market has ... their geographic presence and achieve economies of scale. The ... by 2019 at CAGR of 5.1% from 2014 to ... and a major part of Europe are mature markets ... including China and India, Latin America and the Middle ...
(Date:3/2/2015)... LegitScript, LLC, operator of ... including those for Internet pharmacy certification, monitoring ... classification, has launched a certification program for ... program, called iCareRx , provides certification ... identity of the owner/operator of Internet websites, ...
(Date:3/2/2015)... Pleasant Prairie, WI (PRWEB) March 02, 2015 ... life sciences consultancy focused on quality, regulatory and ... a role as Chief Operating Officer. , ... years of experience leading R&D teams in all ... has held leadership positions at Covidien (Medtronic), Regulatory ...
Breaking Medicine News(10 mins):Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
... The National Osteoporosis,Foundation (NOF) has partnered with CESLIE ... the LeFrak women - a dynamic mother-daughter trio ... dedication to,osteoporosis prevention. Joan Rivers, Melissa Rivers, Jill ... Walsh and Ceslie,Armstrong will host the cocktail soiree ...
... Charitable Contributions Decline Even Though Everyone Benefits ... And Don,t Forget to Claim The Deduction!, NEW YORK, April ... season, is a timely reminder that donating your car is,still a ... seem,to know that because the number of vehicle donations has plummeted ...
... policies could protect patients and physicians from consequences of ... offices and clinics can help prevent the abuse of ... following a stricter policy -- including urine testing --- ... , Implementing a user registry and educating medical staff ...
... British Columbia, April 10 On July,6, 2006, Current ... to the Chairman and to the Chief Executive,Officer, for ... capital of the Company, from his personal holdings, under ... total number of shares under option -- 3,000,000; ...
... Board Expanded to Seven Members, DALLAS, April ... leading healthcare staffing company, today said,that its Board ... (Jay),Dunn to its Board of Directors, effective immediately. ... seven members., John Kaiser, Crdentia,s President and ...
... Receive Grants from Largest and First-of-Its-Kind Fund in ... ... safety and quality of care, Cardinal Health announced,today grants totaling $1 million ... clinics across the country.,This program is the largest and first of its ...
Cached Medicine News:Health News:National Osteoporosis Foundation and CESLIE - The Women's Network Honor LeFrak Mother and Daughters for Commitment to Bone Health and New York Community 2Health News:Tax Season Reminder: Vehicle Donations Still Needed 2Health News:User Registry May Help Docs Stem Painkiller Abuse 2Health News:Keith Denner Extends Current Technology's Chairman and CEO Options 2Health News:Keith Denner Extends Current Technology's Chairman and CEO Options 3Health News:Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 2Health News:Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 3Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 2Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 3Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 4Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 5Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 6
... ACULAR® ophthalmic solution is a prescription ... instruct you to use after your ... eyes and may cause them to ... symptoms of inflammation include redness and ...
Mid-level interpretive resting ECG...
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
... Stat Profile pHOx series consists of six analyzer ... critical care profiles. Measured tests include pH, PCO ... hematocrit, hemoglobin, sodium, potassium, ionized calcium, chloride, glucose, ... than one minute. Its space saving design provides ...
Medicine Products: